Key result
Antithrombin supplementation during extracorporeal membrane oxygenation is being evaluated in a pilot randomized clinical trial to determine its effect on heparin dose requirements, with no results available yet.
Why the study?
Acquired antithrombin deficiency during ECMO is common, but formal recommendations regarding target, timing, and rate of antithrombin supplementation are lacking.
Does antithrombin supplementation reduce the dose of heparin required to maintain adequate anticoagulation in patients requiring veno-venous ECMO for respiratory failure?
RCT (n=40)
Single-blind
Block randomized per center (1:1 ratio)
Yes
Does antithrombin supplementation reduce the dose of heparin required to maintain adequate anticoagulation in patients requiring veno-venous ECMO for respiratory failure?
This study protocol outlines a pilot trial to evaluate whether antithrombin supplementation can decrease heparin requirements and improve anticoagulation adequacy during veno-venous ECMO.
Answers are grounded in this paper and cite their sources.
This pilot RCT will generate initial data on antithrombin in VV-ECMO; larger trials needed before practice change.
Background: Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendation on target, timing, and rate of AT supplementation is lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure. Methods: GATRA is a phase 3, prospective, randomized, single blinded multicenter controlled two-arm trial. Patients undergoing veno-venous ECMO will be randomized to either receive AT supplementation to maintain a functional AT level between 80%-120% (AT supplementation group) or not (control group) for the entire ECMO course. In both study groups anticoagulation will be provided with unfractionated heparin following a standardized protocol. The primary endpoint will be the dose of heparin required to maintain ratio of activated partial thromboplastin time between 1.5-2. Secondary endpoints will be the adequacy of anticoagulation and the incidence of hemorrhagic and thrombotic complications. Discussion: GATRA is a pilot trial that will test the efficacy of a protocol of AT supplementation in decreasing the heparin dose and improving anticoagulation adequacy during ECMO. If positive, it might provide the basis for a future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint including hemorrhagic events, transfusion requirements and mortality. Trial registration ClinicalTrials.gov, NCT03208270. Registered on 5 July 2017.
No takes yet. Share an insight, caveat, or question.
Panigada et al. (2019) conducted an RCT in Severe acute respiratory failure requiring veno-venous ECMO (n=40). Antithrombin supplementation vs. No antithrombin supplementation unless heparin resistance occurs was evaluated on Dose of unfractionated heparin required to maintain aPTT ratio between 1.5-2 (IU/Kg/h). Antithrombin supplementation during extracorporeal membrane oxygenation is being evaluated in a pilot randomized clinical trial to determine its effect on heparin dose requirements, with no results available yet.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: